Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis

被引:62
作者
Ghesquieres, Herve
Berger, Francoise
Felman, Pascale
Callet-Bauchu, Evelyne
Bryon, Paul-Andre
Traverse-Glehen, Alexandra
Thieblemont, Catherine
Baseggio, Lucile
Michallet, Anne-Sophie
Coiffier, Bertrand
Salles, Gilles [1 ]
机构
[1] Univ Lyon 1, Ctr Hosp Lyon Sud, Hematol Serv, F-69495 Pierre Benite, France
[2] Univ Lyon 1, Ctr Hosp Lyon Sud, Serv Anat Pathol, F-69495 Pierre Benite, France
[3] Univ Lyon 1, Hospices Civils Lyon, F-69495 Pierre Benite, France
[4] Univ Lyon 1, Lab Hematol Equipe Accueil Pathol Cellules Lympho, F-69495 Pierre Benite, France
[5] Hop Edouard Herriot, Hematol Lab, Lyon, France
关键词
D O I
10.1200/JCO.2006.07.5671
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Some diffuse large B-cell lymphomas (DLBCL) present at diagnosis with associated morphologic features of small B-cell non-Hodgkin's lymphoma (NHL) and may arise from the transformation of a previously unknown indolent low-grade lymphoma. The characteristics and prognosis of these particular DLBCL are not well known. Patients and Methods The strict morphologic review of consecutive DLBCL patients diagnosed over 12 years in our department (Hematology Department, Centre Hospitalier Lyon-Sud, Lyon, France) allowed to retrieve 60 DLBCL that could be have occurred from the transformation of marginal zone B-cell NHL (32 patients), follicular NHL (22 patients), and small lymphocytic NHL (6 patients). We compared them to 180 matched patients of de novo DLBCL. Results Patients median age was 55 years and presented the following clinical characteristics: poor performance status in 33%, disseminated disease in 97%, more than one extranodal site in 50%, and increased lactate dehydrogenase level in 55%. Complete remission with multidrug chemotherapy regimens was achieved in 60% of the patients, but 48% relapsed: 28% with aggressive and 20% with indolent histology, respectively. Overall survival (OS) and freedom-from-progression rates at 5 years were 57% and 33%, respectively. The matched-control analysis showed that patients with transformed NHL at diagnosis had lower complete response to chemotherapy (P = .004) and higher progression rate (P = .03), whereas no difference was observed in OS (P = .21). Conclusion Compared to de novo DLBCL, transformed NHL at diagnosis have similar overall survival but lower complete response to initial treatment and higher risk of indolent relapses.
引用
收藏
页码:5234 / 5241
页数:8
相关论文
共 35 条
[1]   Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [J].
Alizadeh, AA ;
Eisen, MB ;
Davis, RE ;
Ma, C ;
Lossos, IS ;
Rosenwald, A ;
Boldrick, JG ;
Sabet, H ;
Tran, T ;
Yu, X ;
Powell, JI ;
Yang, LM ;
Marti, GE ;
Moore, T ;
Hudson, J ;
Lu, LS ;
Lewis, DB ;
Tibshirani, R ;
Sherlock, G ;
Chan, WC ;
Greiner, TC ;
Weisenburger, DD ;
Armitage, JO ;
Warnke, R ;
Levy, R ;
Wilson, W ;
Grever, MR ;
Byrd, JC ;
Botstein, D ;
Brown, PO ;
Staudt, LM .
NATURE, 2000, 403 (6769) :503-511
[2]  
[Anonymous], WHO CLASSIFICATION T
[3]   CORRELATION OF SECONDARY CYTOGENETIC ABNORMALITIES WITH HISTOLOGIC APPEARANCE IN NON-HODGKINS LYMPHOMAS BEARING T(14, 18)(Q32, Q21) [J].
ARMITAGE, JO ;
SANGER, WG ;
WEISENBURGER, DD ;
HARRINGTON, DS ;
LINDER, J ;
BIERMAN, PJ ;
VOSE, JM ;
PURTILO, DT .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1988, 80 (08) :576-580
[4]   New approach to classifying non-hodgkin's lymphomas: Clinical features of the major histologic subtypes [J].
Armitage, JO ;
Weisenburger, DD .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) :2780-2795
[5]   Clinicopathologic significance and prognostic value of chromosomal imbalances in diffuse large B-Cell lymphomas [J].
Beà, S ;
Colomo, L ;
López-Guillermo, AL ;
Salaverria, I ;
Puig, X ;
Pinyol, M ;
Rives, S ;
Montserrat, E ;
Campo, E .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (17) :3498-3506
[6]  
CABANILLAS F, 1992, BLOOD, V79, P1024
[7]   Progression to large B-cell lymphoma in splenic marginal zone lymphoma -: A description of a series of 12 cases [J].
Camacho, FI ;
Mollejo, M ;
Mateo, MS ;
Algara, P ;
Navas, C ;
Hernández, JM ;
Santoja, C ;
Solé, F ;
Sánchez-Beato, M ;
Piris, MA .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2001, 25 (10) :1268-1276
[8]   Diffuse large cell lymphoma [J].
Coiffier, B .
CURRENT OPINION IN ONCOLOGY, 2001, 13 (05) :325-334
[9]   BONE-MARROW INVOLVEMENT BY NON-HODGKINS-LYMPHOMA - THE CLINICAL-SIGNIFICANCE OF MORPHOLOGICAL DISCORDANCE BETWEEN THE LYMPH-NODE AND BONE-MARROW [J].
CONLAN, MG ;
BAST, M ;
ARMITAGE, JO ;
WEISENBURGER, DD .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (07) :1163-1172
[10]   Histological grading in gastric lymphoma: Pretreatment criteria and clinical relevance [J].
DeJong, D ;
Boot, H ;
VanHeerde, P ;
Hart, GAM ;
Taal, BG .
GASTROENTEROLOGY, 1997, 112 (05) :1466-1474